Blood Clots and Cancer: Why the Risk Is Higher and How It Is Managed

Research-informed explainer — last updated April 12, 2026

Cancer patients face a 4- to 7-fold higher risk of venous thromboembolism (VTE) — deep vein thrombosis and pulmonary embolism — compared to the general population, and VTE is the second leading cause of death in cancer patients after the cancer itself. Managing this risk requires anticoagulation choices that differ from standard recommendations because of drug interactions with chemotherapy, bleeding risks from thrombocytopenia, and specific complications like heparin-induced thrombocytopenia and hepatic veno-occlusive disease.

This article draws on research from four hematologists who have led or contributed to the major societal guidelines governing anticoagulation in cancer. Adam Cuker, MD, Section Chief of Hematology and Director of the Penn Comprehensive Hemophilia and Thrombosis Program, co-authored the ASH 2020 VTE guidelines (1,356 citations) and the ASH 2018 guidelines on heparin-induced thrombocytopenia (684 citations). Christopher Flowers, MD, Division Head of Cancer Medicine at MD Anderson Cancer Center, contributed to both the ASCO 2019 VTE guidelines for cancer patients (1,429 citations) and the prior 2014 update (1,368 citations) — the most widely used oncology-specific anticoagulation guidance. Nigel Key, MD, Harold R. Roberts Distinguished Professor at UNC, published on the mechanistic basis of cancer-associated thrombosis through the extrinsic coagulation pathway (703 citations), on D-dimer diagnostic utility (675 citations), and contributed to the 2019 international clinical practice guidelines for cancer-associated VTE (642 citations). Paul Richardson, MD, Professor at Harvard Medical School and Clinical Research Director at Dana-Farber, published on hepatic veno-occlusive disease after stem cell transplant (589 citations) — a specialized thrombotic complication relevant to hematology patients undergoing conditioning regimens.

Why cancer raises blood clot risk

The elevated VTE risk in cancer patients has multiple overlapping causes, rooted in all three elements of Virchow's triad (abnormal blood flow, vessel wall injury, and hypercoagulability):

Tumor-driven coagulation activation: Cancer cells express and release tissue factor, the primary initiator of the extrinsic coagulation cascade. Dr. Key's 2007 review in Arteriosclerosis, Thrombosis, and Vascular Biology (703 citations) described how tissue factor-expressing microparticles shed from tumor cells circulate in the bloodstream and activate coagulation at sites distant from the tumor itself. Some cancer types — particularly pancreatic, gastric, ovarian, and brain tumors — are especially thrombogenic for this reason.

Treatment-related risk: Chemotherapy damages endothelial cells, reduces natural anticoagulant proteins, and often necessitates central venous catheters (CVC) that carry their own thrombosis risk. Certain agents — thalidomide, lenalidomide, cisplatin, bevacizumab — carry particularly high VTE risk and require routine prophylaxis in some settings. Hormonal treatments for breast or prostate cancer also elevate clot risk.

Patient-related risk: Immobility during hospitalization, surgery for cancer, and dehydration from nausea and poor oral intake all compound the underlying biological risk.

D-dimer as a marker: Dr. Key's 2008 review on D-dimer (675 citations) clarified that D-dimer — a fibrin degradation product elevated by clot formation — is diagnostically useful for ruling out DVT or PE when negative (high sensitivity) but has low specificity in cancer patients because cancer itself elevates D-dimer. A positive D-dimer in a cancer patient requires imaging to confirm or exclude thrombosis rather than serving as diagnostic on its own.

Which anticoagulant is recommended for cancer-associated VTE?

For most of the history of oncology, low-molecular-weight heparin (LMWH, such as enoxaparin or dalteparin) injected once or twice daily was the standard treatment for cancer-associated DVT and PE, based on randomized trials showing LMWH was more effective than warfarin (vitamin K antagonists) in preventing VTE recurrence in cancer patients, without increasing bleeding.

The ASCO 2019 guidelines updated by Dr. Flowers (1,429 citations) and the corresponding 2014 version (1,368 citations) include a significant change: direct oral anticoagulants (DOACs), specifically rivaroxaban and edoxaban, are now listed as treatment options alongside LMWH for most cancer-associated VTE. Key points from these guidelines include:

• Hospitalized cancer patients with acute illness should receive pharmacologic thromboprophylaxis (LMWH or unfractionated heparin) unless active bleeding or high bleeding risk is present
• Outpatients with cancer who are at high VTE risk (using a validated risk score such as the Khorana score) may be offered prophylaxis with apixaban, rivaroxaban, or LMWH
• For active VTE treatment in cancer patients: LMWH, rivaroxaban, or edoxaban are preferred over warfarin; apixaban is also widely used clinically
• Duration: Anticoagulation is recommended for at least 6 months for cancer-associated VTE, and indefinite continuation should be considered in patients with active cancer or ongoing treatment

The ASH 2020 VTE guidelines led by Dr. Cuker (1,356 citations) affirm the DOAC preference for most patients, with conditional recommendations for home treatment of uncomplicated DVT and PE in patients at low complication risk.

Special considerations for luminal GI cancers and DOACs

A relevant caveat: DOACs carry a higher risk of GI bleeding than LMWH or warfarin, particularly rivaroxaban and edoxaban. For patients with luminal GI cancers (colorectal, gastric, esophageal) — which may already bleed — LMWH may be preferred. Apixaban appears to have a more favorable GI bleeding profile among the DOACs and may be the preferred oral option when GI cancer is present.

Heparin-induced thrombocytopenia (HIT)

HIT is a dangerous immune reaction to heparin that paradoxically causes thrombosis rather than bleeding. Dr. Cuker's group co-authored the ASH 2018 HIT guidelines (684 citations), which recommend:

• Use the 4Ts scoring tool to assess pretest probability before ordering confirmatory HIT tests
• Avoid testing and empiric treatment in patients with a low 4Ts score
• Stop all heparin products immediately if HIT is suspected, and substitute a non-heparin anticoagulant (argatroban, bivalirudin, fondaparinux, or a DOAC depending on clinical context)

HIT is important in the cancer setting because heparin is widely used in hospital prophylaxis and during chemotherapy port flushes. Cancer patients who develop unexplained thrombocytopenia and new thrombosis while on heparin should be evaluated for HIT.

Hepatic veno-occlusive disease: a unique thrombotic complication after transplant

Hepatic veno-occlusive disease (VOD, also called sinusoidal obstruction syndrome) is a serious complication of high-dose conditioning chemotherapy before stem cell transplant, caused by endothelial injury and fibrin deposition in the small hepatic venules. Dr. Richardson's group published a comprehensive study in Biology of Blood and Marrow Transplantation in 2009 (589 citations): in 135 patients at high risk for VOD, the incidence was 8.1%, with a mortality of 84% among those with severe multi-organ failure. VOD is diagnosed by clinical criteria — rapid weight gain, painful hepatomegaly, jaundice — and is treated with defibrotide, the only approved therapy.

Questions to ask your doctor

• Given my cancer type and treatment plan, what is my estimated VTE risk, and should I receive prophylactic anticoagulation?
• If I develop a DVT or pulmonary embolism, should I be treated with a DOAC, LMWH injection, or warfarin — and why?
• Does my cancer type (particularly if it involves the GI tract) affect which anticoagulant is safest for me?
• How long will I need to stay on anticoagulation, and when can it be safely stopped?
• If I develop low platelets during chemotherapy, does that change my anticoagulation plan?
• Should I be evaluated for HIT if I develop new clotting while receiving heparin products?

The bottom line

Cancer substantially elevates VTE risk through tumor-driven coagulation activation, treatment-related endothelial damage, and patient factors like immobility. Guidelines from both ASH and ASCO now support the use of DOACs — particularly apixaban and rivaroxaban — alongside LMWH injections as first-line treatment for most cancer-associated VTE, with LMWH remaining preferred in luminal GI cancers due to bleeding risk. All cancer patients receiving active treatment should have their VTE risk assessed, and high-risk outpatients should have a prophylaxis plan in place.